+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-04-03Number of Pages: 176

Human Microbiome Market (Indication - Gastrointestinal and Metabolic Disorders, Women’s Health, and Cancer; Technology - 16s rRNA Sequencing and Metagenomic Sequencing; Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Women’s Health, and Skin Disorders) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2024

Global Human Microbiome Market: Snapshot

With ample unmet needs, the global market for human microbiome exhibits high potential of growth. The market is set to emerge as a lucrative business in the near future, thanks to the increasing emphasis on diagnosis and treatment of various underrated diseases. The worldwide human microbiome market will be US$2.2 bn in 2020. The lack of targeted drugs for specific conditions, such as ulcerative colitis and C.difficile infection across the world makes this market highly opportune for players to set their innovative drug ideas on the path to commercial success. Driven by these factors, the opportunity in this market is slated to rise at a CAGR of 9.80% between 2020 and 2024 and reach US$3.2 bn by the end of 2024.

Microbiome diagnostics and microbiome therapeutics are the two prominent sections of the global human microbiome market. Currently, the market is in the budding phase, with most of the therapies still being in preclinical or clinical (phase I or phase II) stage. The diagnosis technology is also in the development phase and the leading companies have begun to allocate funds for the research and development and the management of clinical studies for their innovative class of therapies. All these factors are likely to propel this market significantly over the next few years. The human microbiome therapeutics market is likely to report a CAGR of 9.20% during the period of 2020 to 2024, whereas the market for human microbiome diagnostics is anticipated to rise at an 8.60% CAGR between 2018 and 2024.

human microbiome diagnostics market

 

North America to Report Continued Leadership

North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America are the key regional markets for human microbiome across the world. Thanks to the presence of a state-of-art medical and healthcare industry and early adoption of technology, North America has occupied the top position in the global market. Researchers expect that the rising number of venture-capital funded start-ups and the increasing investments by leading players for research and development of drugs will support the North America market for human microbiome over the forthcoming years, ensuring its dominance. The human microbiome therapeutics market in North America is anticipated to report a rise at a CAGR of 9.10% between 2020 and 2024 while the region’s human microbiome diagnostics market will progress at an 8.80% CAGR from 2018 to 2024.

Europe, which acquired the second position in the global human microbiome market, is projected to maintain its position over the years to come. The U.K. and France have emerged as the key domestic markets for human microbiome in Europe. The high investments by companies in this domain are expected to boost both these domestic markets in the next few years. Apart from this, countries, such as Sweden and the Netherlands, are also anticipated to contribute well to the Europe market for human microbiome market in the near future.

Metagenomic Sequencing to Outpace 16s rRNA in Future

On the basis of technology, the global market for human microbiome is classified into 16s rRNA sequencing and metagenomic sequencing. Both the technology are equally popular platforms for detection in the microbiome-based diagnostics. However, the metagenomic sequencing segment is likely to surpass the 16s rRNA segment over the next few years, albeit by a small margin, as a large number of companies are opting for the diagnosis of a more comprehensive microbiome profile.

At the forefront of the global market for human microbiome are Vedanta Biosciences, Synthetic Biologics Inc., Seres Therapeutics, Second Genome, uBiome Inc., Rebiotix Inc., Osel Inc., MicroBiome Therapeutics LLC., Metabiomics Corp., Enterome Biosciences SA, and AO Biome LLC. Some of the other prominent participants in this market are Metabogen AB, Becton Dickinson & Co., Evelo Biosciences, ARTPred, MaaT Pharma, Blue Turtle Bio Technologies, Axial Therapeutics, Whole Biome, 4D Pharma, Symbiotix Therapies, Phi Therapeutics, Synlogic, and Biospherex LLC.

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Human Microbiome Market

Chapter 4. Market Overview
4.1. Introduction
       4.1.1. Market Definition
       4.1.2. Industry Developments
4.2. Market Dynamics
       4.2.1. Drivers
       4.2.2. Restraints
       4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Human Microbiome Market Analysis and Forecasts
       4.4.1. Global Human Microbiome Diagnostics Market Analysis and Forecast, 2018-2024
       4.4.2. Global Human Microbiome Therapeutics Market Analysis and Forecast, 2020-2024
4.5. Global Human Microbiome Market Outlook
4.6. Human Microbiome Therapeutics : Pipeline Overview

Chapter 5. Global Human Microbiome Diagnostics Market Analysis and Forecasts, By Indication 
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
       5.3.1. Gastrointestinal and Metabolic Disorders       
       5.3.2. Women’s Health
       5.3.3. Cancer
       5.3.4. Others
5.4. Market Attractiveness Analysis, by Indication, 2018
5.5. Key Trends 

Chapter 6. Global Human Microbiome Diagnostics Market Analysis and Forecasts, By Technology
6.1. Introduction
6.2. Market Size (US$ Mn) Forecast, by Technology
       6.2.1. 16s rRNA Sequencing
       6.2.2. Metagenomic Sequencing
6.3. Market Attractiveness Analysis, by Technology, 2018
6.4. Key Developments

Chapter 7. Global Human Microbiome Therapeutics Market Analysis and Forecasts, By Therapeutic Area
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Therapeutic Area
       7.3.1. Gastrointestinal Disorders
       7.3.2. Metabolic Disorders
       7.3.3. Women’s Health
       7.3.4. Skin Disorders
       7.3.5. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area, 2020
7.5. Key Trends

Chapter 8. Global Human Microbiome Market Analysis and Forecasts, By Region
8.1. Introduction
8.2. Market Size (US$ Mn) Forecast, by Region
       8.2.1. North America
       8.2.2. Europe
       8.2.3. Asia Pacific
       8.2.4. Latin America       
       8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region, 
       8.3.1. Global Human Microbiome Diagnostics Market (2018)
       8.3.2. Global Human Microbiome Therapeutics Market (2020) 

Chapter 9. North America Human Microbiome Market Analysis and Forecast
9.1. Introduction
9.2. Market Size (US$ Mn) Forecast, by Indication 
       9.2.1. Gastrointestinal and Metabolic Disorders
       9.2.2. Women’s Health
       9.2.3. Cancer
       9.2.4. Others
9.3. Market Size (US$ Mn) Forecast, by Technology
       9.3.1. 16s rRNA Sequencing
       9.3.2. Metagenomic Sequencing
9.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
       9.4.1. Gastrointestinal Disorders
       9.4.2. Metabolic Disorders
       9.4.3. Women’s Health
       9.4.4. Skin Disorders
       9.4.5. Others
9.5. Market Size (US$ Mn) Forecast, by Country
       9.5.1. U.S.
       9.5.2. Canada
9.6. Market Attractiveness Analysis, by Indication, 2018
9.7. Market Attractiveness Analysis, by Technology, 2018
9.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
9.9. Key Trends

Chapter 10. Europe Human Microbiome Market Analysis and Forecast
10.1. Introduction
10.2. Market Size (US$ Mn) Forecast, by Indication 
       10.2.1. Gastrointestinal and Metabolic Disorders
       10.2.2. Women’s Health
       10.2.3. Cancer
       10.2.4. Others
10.3. Market Size (US$ Mn) Forecast, by Technology
       10.3.1. 16s rRNA Sequencing
       10.3.2. Metagenomic Sequencing
10.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
       10.4.1. Gastrointestinal Disorders
       10.4.2. Metabolic Disorders
       10.4.3. Women’s Health
       10.4.4. Skin Disorders
       10.4.5. Others
10.5. Market Size (US$ Mn) Forecast, by Country
       10.5.1. U.K.
       10.5.2. Germany
       10.5.3. Rest of Europe
10.6. Market Attractiveness Analysis, by Indication, 2018
10.7. Market Attractiveness Analysis, by Technology, 2018
10.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
10.9. Key Trends

Chapter 11. Asia Pacific Human Microbiome Market Analysis and Forecast
11.1. Introduction
11.2. Market Size (US$ Mn) Forecast, by Indication 
       11.2.1. Gastrointestinal and Metabolic Disorders
       11.2.2. Women’s Health
       11.2.3. Cancer
       11.2.4. Others
11.3. Market Size (US$ Mn) Forecast, by Technology
       11.3.1. 16s rRNA Sequencing
       11.3.2. Metagenomic Sequencing
11.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
       11.4.1. Gastrointestinal Disorders
       11.4.2. Metabolic Disorders       
       11.4.3. Women’s Health
       11.4.4. Skin Disorders
       11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Country
       11.5.1. China
       11.5.2. Japan
       11.5.3. Rest of Asia Pacific
11.6. Market Attractiveness Analysis, by Indication, 2018
11.7. Market Attractiveness Analysis, by Technology, 2018
11.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
11.9. Key Trends

Chapter 12. Latin America Human Microbiome Market Analysis and Forecast
12.1. Introduction 
12.2. Market Size (US$ Mn) Forecast, by Indication 
       12.2.1. Gastrointestinal and Metabolic Disorders
       12.2.2. Women’s Health
       12.2.3. Cancer
       12.2.4. Others
12.3. Market Size (US$ Mn) Forecast, by Technology
       12.3.1. 16s rRNA Sequencing
       12.3.2. Metagenomic Sequencing
12.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
       12.4.1. Gastrointestinal Disorders
       12.4.2. Metabolic Disorders
       12.4.3. Women’s Health
       12.4.4. Skin Disorders
       12.4.5. Others 
12.5. Market Size (US$ Mn) Forecast, by Country
       12.5.1. Brazil
       12.5.2. Mexico
       12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis, by Indication, 2018
12.7. Market Attractiveness Analysis, by Technology, 2018
12.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
12.9. Key Trends

Chapter 13. Middle East & Africa Human Microbiome Market Analysis and Forecast
13.1. Introduction 
13.2. Market Size (US$ Mn) Forecast, by Indication 
       13.2.1. Gastrointestinal and Metabolic Disorders
       13.2.2. Women’s Health
       13.2.3. Cancer
       13.2.4. Others
13.3. Market Size (US$ Mn) Forecast, by Technology
       13.3.1. 16s rRNA Sequencing
       13.3.2. Metagenomic Sequencing
13.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
       13.4.1. Gastrointestinal Disorders
       13.4.2. Metabolic Disorders
       13.4.3. Women’s Health
       13.4.4. Skin Disorders
       13.4.5. Others 
13.5. Market Size (US$ Mn) Forecast, by Country
       13.5.1. UAE
       13.5.2. South Africa
       13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis, by Indication, 2018
13.7. Market Attractiveness Analysis, by Technology, 2018
13.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
13.9. Key Trends

Chapter 14. Competition Landscape
14.1. Company Profiles
       14.1.1. AO Biome LLC 
                 14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                 14.1.1.2. Recent Developments
                 14.1.1.3. Product Portfolio
                 14.1.1.4. SWOT Analysis
                 14.1.1.5. Strategic Overview
       14.1.2. Enterome Biosciences SA
                 14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                 14.1.2.2. Product Portfolio
                 14.1.2.3. SWOT Analysis
                 14.1.2.4. Strategic Overview
       14.1.3. Metabiomics Corp.
                 14.1.3.1. Company Overview (HQ, business segments, employee strength)
                 14.1.3.2. Product Portfolio
                 14.1.3.3. SWOT Analysis
                 14.1.3.4. Recent Developments
                 14.1.3.5. Strategic Overview
       14.1.4. MicroBiome Therapeutics LLC
                 14.1.4.1. Company Overview (HQ, business segments, employee strength)
                 14.1.4.2. Product Portfolio
                 14.1.4.3. SWOT Analysis
                 14.1.4.4. Strategic Overview
                 14.1.4.5. Recent Developments
       14.1.5. Osel, Inc.
                 14.1.5.1. Company Overview (HQ, business segments, employee strength)
                 14.1.5.2. Clinical Trial Candidates
                 14.1.5.3. Product Portfolio
                 14.1.5.4. SWOT Analysis
                 14.1.5.5. Strategic Overview
       14.1.6. Rebiotix, Inc.
                 14.1.6.1. Company Overview (HQ, business segments, employee strength)
                 14.1.6.2. Product Portfolio
                 14.1.6.3. SWOT Analysis
                 14.1.6.4. Recent Developments
                 14.1.6.5. Strategic Overview
       14.1.7. uBiome, Inc.
                 14.1.7.1. Company Overview (HQ, business segments, employee strength)
                 14.1.7.2. Recent Developments
                 14.1.7.3. Product Portfolio
                 14.1.7.4. SWOT Analysis
                 14.1.7.5. Strategic Overview
       14.1.8. Second Genome
                 14.1.8.1. Company Overview (HQ, business segments, employee strength)
                 14.1.8.2. Financial Overview: Funding and Investments
                 14.1.8.3. Product Portfolio
                 14.1.8.4. SWOT Analysis
                 14.1.8.5. Strategic Overview
       14.1.9. Seres Therapeutics
                 14.1.9.1. Company Overview (HQ, business segments, employee strength)
                 14.1.9.2. Product Portfolio
                 14.1.9.3. Financial Overview
                 14.1.9.4.  SWOT Analysis
                 14.1.9.5. Strategic Overview
       14.1.10. Synthetic Biologics, Inc.
                 14.1.10.1. Company Overview (HQ, business segments, employee strength)
                 14.1.10.2. Product Portfolio
                 14.1.10.3. Financial Overview
                 14.1.10.4. SWOT Analysis
                 14.1.10.5. Strategic Overview
       14.1.11. Vedanta Biosciences
                 14.1.11.1. Company Overview (HQ, business segments, employee strength)
                 14.1.11.2. Product Portfolio
                 14.1.11.3. Recent Developments
                 14.1.11.4. SWOT Analysis
                 14.1.11.5. Strategic Overview
       14.1.12. Others
                 14.1.12.1. Metabogen AB
                 14.1.12.2. Becton Dickinson & Company
                 14.1.12.3. Evelo Biosciences
                 14.1.12.4. ARTPred
                 14.1.12.5. MaaT Pharma
                 14.1.12.6. Blue Turtle Bio Technologies
                 14.1.12.7. Axial Therapeutics
                 14.1.12.8. Whole Biome
                 14.1.12.9. 4D Pharma
                 14.1.12.10. Symbiotix Therapies
                 14.1.12.11. Phi Therapeutics
                 14.1.12.12. Synlogic
                 14.1.12.13. Biospherex LLC

List of Figures

Figure 1: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2024
Figure 2: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2024
Figure 3: Human Microbiome Diagnostic Market Value Share By Indication (2018)
Figure 4: Human Microbiome Diagnostic Market Value Share By Technology (2018)
Figure 5: Human Microbiome Therapeutics Market Value Share By Therapeutic Area (2020)
Figure 6: Human Microbiome Therapeutics Market Value Share By Region (2020)
Figure 7: Global Human Microbiome Diagnostic Market Value Share Analysis, by Indication, 2018 and 2024
Figure 8: Global GI & Metabolic Disorders Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2024
Figure 9: Global Women’s Health Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2024
Figure 10: Global Cancer Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2024
Figure 11: Global Others Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2024
Figure 12: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Indication, 2018
Figure 13: Global Human Microbiome Diagnostic Market Value Share Analysis, by Technology, 2018 and 2024
Figure 14: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Technology, 2018
Figure 15: Global Metagenomic Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2024
Figure 16: Global 16s rRNA Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2024
Figure 17: Global Human Microbiome Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 18: Global GI Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2024
Figure 19: Global Metabolic Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2024
Figure 20: Global Women’s Health Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2024
Figure 21: Global Skin Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2024
Figure 22: Global Others Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2024
Figure 23: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 25: Global Human Microbiome Therapeutics Market Value Share Analysis, by Region, 2020 and 2024
Figure 24: Global Human Microbiome Diagnostics Market Value Share Analysis, by Region, 2018 and 2024
Figure 27: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Region, 2020
Figure 26: Global Human Microbiome Diagnostics Market Attractiveness Analysis, by Region, 2018
Figure 28: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2024
Figure 29: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2024
Figure 30: North America Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 31: North America Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 32: North America Diagnostic Market Value Share Analysis, by Indication, 2018 and 2024
Figure 33: North America Diagnostic Market Value Share Analysis, by Technology, 2018 and 2024
Figure 34: North America Diagnostic Market Value Share Analysis, by Country, 2018 and 2024
Figure 35: North America Therapeutics Market Value Share Analysis By Therapeutic Area, 2020 and 2024
Figure 36: North America Therapeutics Market Value Share Analysis By Country, 2020 and 2024
Figure 37: North America Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 38: North America Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 39: North America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 40: Europe Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2024
Figure 41: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2024
Figure 42: Europe Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 43: Europe Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 44: Europe Diagnostic Market Value Share Analysis, by Indication, 2018 and 2024
Figure 45: Europe Diagnostic Market Value Share Analysis, by Technology, 2018 and 2024
Figure 46: Europe Diagnostic Market Value Share Analysis, by Country, 2018 and 2024
Figure 47: Europe Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 48: Europe Therapeutics Market Value Share Analysis, by Country, 2020 and 2024
Figure 49: Europe Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 50: Europe Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 51: Europe Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 52: Asia Pacific Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2024
Figure 53: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2024
Figure 54: Asia Pacific Diagnostics Market Attractiveness Analysis, by Country
Figure 55: Asia Pacific Therapeutics Market Attractiveness Analysis, by Country
Figure 56: Asia Pacific Diagnostic Market Value Share Analysis, by Indication, 2018 and 2024
Figure 57: Asia Pacific Diagnostic Market Value Share Analysis, by Technology, 2018 and 2024
Figure 58: Asia Pacific Diagnostic Market Value Share Analysis, by Country, 2018 and 2024
Figure 59: Asia Pacific Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 60: Asia Pacific Therapeutics Market Value Share Analysis, by Country, 2020 and 2024
Figure 61: Asia Pacific Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 62: Asia Pacific Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 63: Asia Pacific Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 64: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2024
Figure 65: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2024
Figure 66: Latin America Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 67: Latin America Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 68: Latin America Diagnostics Market Value Share Analysis, by Indication, 2018 and 2024
Figure 69: Latin America Diagnostics Market Value Share Analysis, by Technology, 2018 and 2024
Figure 70: Latin America Diagnostics Market Value Share Analysis, by Country, 2018 and 2024
Figure 71: Latin America Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 72: Latin America Therapeutics Market Value Share Analysis, by Country, 2020 and 2024
Figure 73: Latin America Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 74: Latin America Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 75: Latin America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 76: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2024
Figure 77: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2024
Figure 78: Middle East & Africa Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 79: Middle East & Africa Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 80: Middle East & Africa Diagnostics Market Value Share Analysis, by Indication, 2018 and 2024
Figure 81: Middle East & Africa Diagnostics Market Value Share Analysis, by Technology, 2018 and 2024
Figure 82: Middle East & Africa Diagnostics Market Value Share Analysis, by Country, 2018 and 2024
Figure 83: Middle East & Africa Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 84: Middle East & Africa Therapeutics Market Value Share Analysis, by Country, 2020 and 2024
Figure 85: MEA Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 86: MEA Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 87: MEA Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020

List of Tables

Table 1: Pipeline Scenario
Table 2: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018–2024
Table 3: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018–2024
Table 4: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2024
Table 5: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Region
Table 6: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Region
Table 7: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018–2024
Table 8: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018–2024
Table 9: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018–2024
Table 10: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2024
Table 11: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2024
Table 12: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018–2024
Table 13: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018–2024
Table 14: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 2018–2024
Table 15: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2024
Table 16: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2024
Table 17: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018–2024
Table 18: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018–2024
Table 19: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 2018–2024
Table 20: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2024
Table 21: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2024
Table 22: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018–2024
Table 23: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018–2024
Table 24: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018–2024
Table 25: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area,
Table 26: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2024
Table 27: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication,
Table 28: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology,
Table 29: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018–2024
Table 30: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2024
Table 31: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country

 

Global Human Microbiome Market: Overview

The human microbiome also known as microbiota is composed of population of microbes such as fungi, bacteria and archaea. These microbes reside on the surface or in the deep layers of skin in oral mucosa, the saliva, gastrointestinal tracts and in the conjunctiva. At present, extensive research is being conducted to discover the importance of these micro-organisms in maintaining immune systems and contributing to digestion of food.

Large number of microbes reside in the large intestine, with region of the human body having a distinct community of microbes dwelling. Studies are still in progress to understand the factors regulating microbial colonization in areas of the body that are just millimeters apart. The Human Microbiome Project (HMP) was launched in 2008 as a U.S. National Institute of Health. This was initiated with a goal of identifying and characterizing the microbes found within the healthy and diseases human body.

Global Human Microbiome Market: Scope of the Study

This report on the global human microbiome market analyzes the future prospects of the market. The market for diagnostics and therapeutics is independently analyzed as two separate markets within the report. The market for microbiome therapeutics is segmented based on therapeutic area and region, while the market for microbiome diagnostics is segmented on the basis of indication, technology and region.

It comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2018 and 2024 for diagnostics and 2020 to 2024 for therapeutics, along with the compound annual growth rate (CAGR %) from 2018/20 to 2024 are provided for all the segments.

Market related factors such as new product launches, drugs in the pipeline, industry-institute collaborations in research for finding a pertinent cure, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the global human microbiome market have been determined after a thorough analysis of past and present trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Global Human Microbiome Market: Segmentation

Based on indication, the global human microbiome diagnostics market has been segmented into Gastrointestinal and Metabolic disorders, Women’s Health, Cancer and Others. Gastrointestinal & metabolic disorders are likely to show most promising growth in the market owing to the higher unmet medical need for gut health disorders as well as a rise in population suffering from faulty- lifestyle based metabolic diseases.

Based on technology, the market has been segmented into 16s rRNA sequencing and metagenomic sequencing. Both the forms have been documented to have various advantages with regard to accurate testing and hence, both these segments garner nearly equal share of the overall diagnostics market during the forecast period. Based on therapeutic area, the market has been segmented into Gastrointestinal Disorders, Metabolic disorders, Women’s Health, Skin Disorders and Others. Other therapeutic areas include autoimmune disorders, infant health disorders, and rare diseases.

Geographically, the global human microbiome market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries. These include the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, the UAE, and South Africa. The competition landscape section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the human microbiome market.

Companies Mentioned in the Study

The report profiles major players in the human microbiome market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AOBiome LLC, Osel Inc., Seres Therapeutics, Second Genome, uBiome Inc., Metabiomics Corp., Rebiotix Inc., Vedanta Biosciences etc.

The global human microbiome market has been segmented as follows:

By Indication

  • Gastrointestinal and Metabolic Disorders
  • Women’s Health
  • Cancer
  • Others

By Technology

  • 16s rRNA Sequencing
  • Metagenomic Sequencing

By Therapeutic Area

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Women’s Health
  • Skin Disorders
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • UAE
    • South Africa
    • Rest of Middle East and Africa


 
 
Back To Top